Heart Failure: The Missing 800 Pound Gorilla In Diabetes Trials

Is heart failure the missing 800 pound gorilla in diabetes trials? That’s the argument proposed by a group of  prominent cardiovascular and diabetes researchers. It was long believed that by virtue of their glucose-lowering properties diabetes drugs would confer substantial cardiovascular benefits. Now, however, that belief is no longer widely held and the FDA now requires cardiovascular outcome trials for new diabetes drugs. But, write the researchers in  an article published in The Lancet Diabetes & Endocrinology, these trials are failing to track and analyze one key cardiovascular endpoint, thereby diminishing the value of these trials in assessing More…
Source: CardioBrief - Category: Cardiology Authors: Tags: Policy & Ethics Prevention, Epidemiology & Outcomes Avandia diabetes glucose control heart failure rosigliitazone Source Type: blogs